Download PDF
Thromb Haemost 1996; 75(04): 696-697
DOI: 10.1055/s-0038-1650348
Letter to the Editor
Schattauer GmbH Stuttgart

Pseudo Factor XII Deficiency and Phospholipid Antibodies

D W Jones
The Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, Ethelbert Road, Canterbury, Kent, UK
,
M J Gallimore
The Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, Ethelbert Road, Canterbury, Kent, UK
,
M Winter
The Haemophilia Centre, Kent and Canterbury Hospitals NHS Trust, Ethelbert Road, Canterbury, Kent, UK
› Author Affiliations
Further Information

Publication History

Received 16 October 1995

Accepted after revision 18 December 1995

Publication Date:
10 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints
 

  • References

  • 1 Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine 1983; 62: 248-255
    CrossrefPubMedSearch in Google Scholar
  • 2 Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1: 259-263
    PubMedSearch in Google Scholar
  • 3 Winter M, Gallimore M, Jones DW. Should Factor XII assays be included in thrombophilia screening?. Lancet 1995; 346: 52
    CrossrefPubMedSearch in Google Scholar
  • 4 Gallimore MJ, Rees WA, Fuhrer G, Heller W. A direct chromogenic peptide substrate assay for Hageman factor (FXII). Fibrinolysis 1987; 1: 123-127
    PubMedSearch in Google Scholar
  • 5 Jones DW, Winter M. The use of a Clinical Chemistry analyser for the automation of chromogenic assays. Thromb Haemost 1993; 69 (06) 864
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Loizou S, McRea JD, Rudge AC, Reynolds R, Boyle C, Harris EN. Measurement of anticardiolipin antibodies by an enzyme linked immuno-sorbant assay: standardisation and quantitation of results. Clinical and Experimental Immunology 1985; 62: 738-745
    PubMedSearch in Google Scholar
  • 7 Jaeger U, Kapiotis S, Pabinger I, Puchhammer E, Kyrle P, Lechner K. Transient lupus anticoagulant associated with hypoprothrombinaemia and factor XII deficiency following adenovirus infection. Annals Haematol 1993; 67 (02) 95-99
    PubMedSearch in Google Scholar
  • 8 Endo Y. Congenital factor XII deficiency and lupus anticoagulant. Internal Medicine 1994; 33 (03) 188
    CrossrefPubMedSearch in Google Scholar
  • 9 Brookfield C, Malia RG, Cooper SM, Greaves M. Factor XII levels and the Lupus Anticoagulant. Thromb Haemost 1995; 73 (06) 1441
    PubMedSearch in Google Scholar
  • 10 Schousboe I. β2-glycoprotein 1: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-1091
    PubMedSearch in Google Scholar
  • 11 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein-1 (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
    CrossrefPubMedSearch in Google Scholar
  • 12 Galli M, Cortelazzo S, Daldossi M, Barbui T. Increased levels of β2-glycoprotein-1 (aca co-factor) in patients with lupus anticoagulant. Thromb Haemost 1992; 67: 386
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Harris EN. Antiphospholipid antibodies (Annotation). British Journal of Haematology 1990; 74: 1-9
    PubMedSearch in Google Scholar